Data source and study cohort
OPSCC, Cancer
CANCER
From the Taiwan Cancer Registry Database (TCRD), we enrolled patients who had received a diagnosis of p16-negative OPSCC between January 1, 2008, and December 31, 2018. The follow-up duration was from the index date to December 31, 2019. Biomarkers commonly used in clinical practice include p16 expression (determined through immunohistochemistry) and HPV 16 viral load (detected through real-time polymerase chain reaction) [